Genetically Encoded Photo-cross-linkers Map the Binding Site of an Allosteric Drug on a G Protein-Coupled Receptor by Grunbeck, Amy et al.
  1 
SUPPLEMENTARY INFORMATION FOR 
 
 
Genetically-encoded Photocrosslinkers Map the Binding Site of an 
Allosteric Drug on a G Protein-coupled Receptor 
 
Amy Grunbeck†, Thomas Huber†, Ravinder Abrol‡, Bartosz Trzaskowski‡, William 
A. Goddard, III‡, Thomas P. Sakmar*,† 
 
†Laboratory of Molecular Biology & Biochemistry, The Rockefeller University, 
1230 York Ave., New York, NY  10065.  www.sakmarlab.org 
 
‡Materials and Process Simulation Center (MC 139-74), California Institute of 
Technology, 1200 E California Blvd, Pasadena, CA 91125, United States. 
 
Contents: 





I. Supplementary Figures 
 
Supplementary Figure 1 Photocrosslinking results with CCR5 azF mutants. 
This data set is from the same experiment that is shown in Figure 2a, except 
here we include the control sample for each mutant that was not exposed to UV 
light.  The three bar graphs shown here display the amount of tritium detected in 
the 50 – 100 kDa segment (a), 25 – 50 kDa segment (b), and 15 – 25 kDa 
segment (c). This data shows that the elevated levels of tritium detected in the 25 
– 50 kDa segment for the I28 and W86 mutants is UV-specific. This supports the 
conclusion that these increases in tritium levels at the molecular weight of the 
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receptor are a result of a covalent crosslink between the azF at positions I28 and 




Supplementary Figure 2 Photocrosslinking results with CCR5 BzF mutants. 
This data set is from the same experiment that is shown in Figure 2b, except 
here we include the control sample for each mutant that was not exposed to UV 
light.  The three bar graphs shown here display the amount of tritium detected in 
the 50 – 100 kDa segment (a), 25 – 50 kDa segment (b), and 15 – 25 kDa 
segment (c). This data shows that the elevated levels of tritium detected in the 25 
– 50 kDa segment for the I28 and F109 mutants is UV-specific. This supports the 
conclusion that these increases in tritium levels at the molecular weight of the 
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receptor are a result of a covalent crosslink between the BzF at positions I28 and 




Supplementary Figure 3 CCR5 UAA mutants retain binding to maraviroc. Each 
of the CCR5 UAA mutants was measured for their ability to bind maraviroc under 
the conditions of the crosslinking experiments. In brief, after the HEK293T cells 
expressing the CCR5 UAA mutants were incubated with [3H]-maraviroc, exposed 
to UV light and then solubilized in detergent, the receptors were then 
immunopurified from the lysate using sepharose beads conjugated to the 1D4 
mAb. The beads were then washed, samples were eluted using SDS, and the 
amount of tritium in the elution was quantified. The [3H]-maraviroc detected in the 
elution was determined to be a result of being specifically bound to the purified 
receptor.  This was supported by no tritium was detected in the sample with the 
homologous receptor, CXCR4, which is unable to bind maraviroc. Therefore the 
amount of tritium in the eluted samples was quantified for each CCR5 UAA 
mutant to determine the amount of [3H]-maraviroc that was specifically bound. 
The values were then normalized to each other by setting the amount of tritium 
that was bound to WT CCR5 as an equivalent to 100% binding. The error bars 
are a result of averaging the values obtained from the sample that was exposed 
to UV light with the sample that was not. The differences in binding between the 
mutants are a result of varied expression levels of each of the mutants and 
differences in binding affinity for maraviroc. This graph shows that all of the 





Supplementary Figure 4 Western Blots showing the expression level of each of 
the CCR5 UAA mutants.  The Western Blots shown above were immunoblotted 
with the 1D4 mAb, which recognizes an epitope at the C-terminus of the 
receptor.  The band corresponding to CCR5 is indicated with the arrow at 37 
kDa. The other prominent band at 25 kDa is the light chain of the 1D4 antibody 
that was used to immunopurify these samples.  The exposure of each of these 
blots is not normalized to each other.  The samples shown in (a) are from the azF 
experiments and (b) shows the samples from the BzF experiments. These 
membranes were then cut at specific molecular weights and counted to 




Structure prediction of the CCR5-maraviroc complex. 
1. GEnSeMBLE(1) procedure for generating an ensemble of GPCR 
conformations: 
A. Predict transmembrane (TM) helix regions of the receptor: 
Use PredicTM to predict TM regions based on the octanol hydrophobicity 
scale(2) and extend those regions based on helix predictions from the 
secondary structure servers. 
B. Generate template for protein bundle: 
i. Mutate TM helix bundles of multiple crystal templates [bovine 
rhodopsin (PDB ID: 1u19), human β2 adrenergic receptor (2rh1), 
human adenosine A2A receptor (3eml), and turkey β1 adrenergic 
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receptor (2vt4)] to CCR5 sequence to generate 4 starting structures 
for the following conformational sampling. 
C. Sample completely the ensemble of seven-helix bundle conformations: 
i. BiHelix:(3) Sample helix rotation angle (η) for all pairs of interacting 
helices. Use SCREAM (SideChain Rotamer Excitation Analysis 
Method)(4) to optimize sidechain interactions for each sampled 
conformation and minimize the sidechains for 10 steps. Combine all 
BiHelix energies as described here(3) and order by energy. 
ii. CombiHelix: Build the top 2000 conformations from previous step, and 
use SCREAM with 10-step minimization to optimize sidechain 
interactions. 
iii. Comparing the interhelical energies for these conformations for each 
of the 4 starting structures, showed that the β2 crystal template 
resulted in the lowest energy helix packing conformations for CCR5. 
iv. SuperBiHelix: Take the 16 diverse lowest energy conformations from 
previous step to sample, for each conformation, helix tilt angle (θ), 
sweep angle (ϕ), and rotation angle (η) for all pairs of interacting 
helices, and use SCREAM with 10-step minimization to optimize 
sidechain interactions. Combine all SuperBiHelix energies as 
described here(3) and order by energy. 
v. SuperCombiHelix: Take the top 2000 conformations from previous 
step, and use SCREAM with 10-step minimization to optimize 
sidechain interactions. 
vi. Choose the lowest energy structures from SuperCombiHelix 
according to the average of the charged total energy rank, neutralized 
total energy rank, charged interhelical energy rank, and neutralized 
interhelical energy rank (Average Energy Rank). 
2. Docking of Maraviroc to 8 diverse lowest energy conformations of CCR5 
A. Ligand preparation 
i. The ligand maraviroc was built and minimized in Maestro/Macromodel 
program. Quantum mechanics calculations (B3LYP/6-311G** using 
Jaguar 7 software, Jaguar, version 7.6, Schrödinger, LLC, New York, 
NY, 2009.) were performed to obtain partial charges as well as 
calculate the pKa values of selected Nitrogen atoms. 
ii.  Maestro/Macromodel was used to perform a long conformational 
search, which after additional clustering yielded ~25 diverse Maraviroc 
conformations. 
B. Ligand docking 
i. In our docking approach we used DOCK 6(5) to generate a large 
number (~50000) of ligand poses in the potential binding regions. The 
resulting ligand poses were clustered using 1.2 Å diversity until the % 
of new families (containing only poses from the current generation) 
became less than 5% to ensure completeness. 
ii. This step was followed by the energy scoring of family heads using 
polar, phobic and total energies. Top 100 poses from each energy 
scoring and additionally top 10 poses from each ligand conformation 
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were chosen for further optimization, which included dealanization of 
protein, neutralization of the protein-ligand complex and complex 
minimization. All optimization steps were performed independently for 
each of the eight CCR5 models using the DREIDING force field(6). 
The lowest total energy complex was chosen as the final CCR5-
maraviroc complex model. This corresponded to the 7th lowest energy 
predicted apo CCR5 conformation. 
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